P. Fra

In Vitro and In Vivo Effect of Thymostimulin in Melanoma Patients

M. Bernengo, M. Bernengo, M. Novelli, 1984 .

COVID-19 in melanoma patients: Results of the Spanish Melanoma Group Registry, GRAVID study

S. Puig, R. Rosell, M. Provencio, 2021, Journal of the American Academy of Dermatology.

Thymostimulin therapy in melanoma patients: correlation of immunologic effects with clinical course.

M. Bernengo, F. Lisa, M. Meregalli, 1983, Clinical immunology and immunopathology.

Phase II trial of gemcitabine plus rapamycin as second line in advanced osteosarcoma: A Spanish Group for Sarcoma Research (GEIS) Study.

J. Mora, C. Valverde, J. Broto, 2015 .

Phase II multicenter, single arm, open label study of nivolumab (NIVO) in combination with ipilimumab (IPI) as first line in adult patients (pts) with metastatic uveal melanoma (MUM): GEM1402 NCT02626962.

E. Espinosa, D. Rodríguez-Abreu, J. Piulats, 2017 .

Characteristics and outcomes of advanced melanoma patients with complete response and elective discontinuation of first‐line anti‐programmed death‐1 monotherapy: A real‐world multicentre observational cohort study

S. Ochenduszko, J. P. Altozano, R. D. Beveridge, 2023, Pigment cell & melanoma research.

Trabectedin and radiotherapy in soft-tissue sarcoma (TRASTS) study: An international, prospective, phase II trial in localized myxoid liposarcoma—A collaborative Spanish (GEIS), Italian (ISG) and French (FSG) group study.

J. Blay, A. Gronchi, C. Morosi, 2020 .